Protagonist director exercises options, sells 24K shares

Protagonist Therapeutics director Harold E. Selick reported an option exercise and share sale.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Protagonist Therapeutics director Harold E. Selick reported an option exercise and share sale. He exercised stock options for 24,000 shares of common stock at $12.88 per share, converting fully vested options into common shares.

On the same date, he then sold 24,000 common shares at $105.00 per share in an open-market transaction. Following these transactions, Selick directly holds 60,845 shares of Protagonist Therapeutics common stock.

Insider Trade Summary

Exercise and Sale: 24,000 shares ($2.21M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider SELICK HAROLD E

Role Director

Sold 24,000 shs ($2.52M)

Approx. gross sale proceeds $2.52M

Approx. exercise cost $309K

Approx. pre-tax spread $2.21M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	24,000	$0.00	$0.00
Exercise	Common Stock	24,000	$12.88	$309K
Sale	Common Stock	24,000	$105.00	$2.52M

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 60,845 shares (Direct)

Footnotes (1)

F1. These stock options are fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Protagonist Therapeutics (PTGX) director Harold Selick report?

Harold E. Selick reported exercising options for 24,000 Protagonist Therapeutics shares at $12.88, then selling 24,000 common shares at $105.00. After these transactions, he directly holds 60,845 Protagonist Therapeutics common shares.

How many Protagonist Therapeutics (PTGX) shares did Harold Selick sell and at what price?

Harold E. Selick sold 24,000 shares of Protagonist Therapeutics common stock at $105.00 per share in an open-market transaction. This sale occurred after he exercised stock options for the same number of shares on the same date.

How many Protagonist Therapeutics (PTGX) shares does Harold Selick hold after this Form 4?

Following the reported transactions, Harold E. Selick directly holds 60,845 shares of Protagonist Therapeutics common stock. This figure reflects his position after exercising stock options and selling 24,000 shares on the reported transaction date.

What stock options did Harold Selick exercise in Protagonist Therapeutics (PTGX)?

Harold E. Selick exercised stock options covering 24,000 shares of Protagonist Therapeutics common stock at an exercise price of $12.88 per share. The filing notes these stock options are fully vested at the time of the transaction.

Was Harold Selick’s Protagonist Therapeutics (PTGX) transaction an open-market sale?

Yes. The Form 4 describes Harold E. Selick’s disposition of 24,000 Protagonist Therapeutics common shares as a sale in the open market or a private transaction, using transaction code "S" for an open-market sale.

Did Harold Selick retain any exercised options in Protagonist Therapeutics (PTGX)?

The reported options for 24,000 shares were exercised in full, and the derivative section shows no remaining derivative positions from this grant. After the exercise and related sale, his remaining exposure is through 60,845 directly held common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/27/2026 - 07:34 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SELICK HAROLD E

(Last)

(First)

(Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK

CALIFORNIA

94560-1160

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/26/2026		M		24,000	A	$12.88	84,845	D
Common Stock	03/26/2026		S		24,000	D	$105	60,845	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$12.88	03/26/2026		M			24,000	⁽¹⁾	09/13/2026	Common Stock	24,000	$0.00	0	D

Explanation of Responses:

1. These stock options are fully vested.

	/s/ Matthew Gosling, Attorney-in-Fact for Harold E. Selick	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR